Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Andrew D. White is an Associate Professor of Chemical Engineering at the Hajim School of Engineering & Applied Sciences, University of Rochester. He holds a PhD from the University of Washington (2013). His research focuses on automating scientific discovery through AI, particularly leveraging large language models (LLMs) and deep learning techniques in chemistry. His lab develops agents that integrate literature analysis, hypothesis generation, and experimental design to advance fields like molecular dynamics and drug discovery. Education: PhD in Chemical Engineering, University of Washington, 2013 BS/MS (not explicitly stated in text, inferred from career timeline) Research Interests: Large language models for scientific automation Deep learning applications in chemistry and materials science Molecular dynamics simulations Scientific agents and autonomous systems Publications: His work includes groundbreaking studies on closed-loop AI systems for chemistry, federated learning in molecular property prediction, and multi-agent systems for drug discovery. Recent highlights include the Robin system and ChemCrow tools. Awards: Recipient of the NSF Career Award (2018), NIH Outstanding Investigator Award (2020), and the Curtis Teaching Award (2019). He also advises biotech companies and serves on the National Academy of Sciences' Chemical Sciences Roundtable. Grants & Funding: Supported by DOE, NSF (multiple grants including CBET-1751471), NIH (R35GM137966), and LLNL projects. Collaborates with institutions like Argonne National Lab and Qubit Pharmaceuticals. Labs & Teams: Leads the White Lab at Rochester and co-founded FutureHouse, a nonprofit advancing AI-driven scientific discovery. Supervises a multidisciplinary team of PhD students and postdocs in computational chemistry, AI, and biophysics.
Pim de Vink is a doctoral researcher at Eindhoven University of Technology , affiliated with the Biomedical Engineering department and Chemical Biology group. Supervised by dr. L.-G. Milroy and prof. L. Brunsveld , his work bridges supramolecular chemistry and chemical biology , focusing on host/guest chemistry for protein complex modulation. Education: B.Sc. in Chemistry (2014) from University of Amsterdam M.Sc. in Biomedical Engineering (2016) from TU/e Internship at Max Planck Institute for Molecular Physiology (2016) on gold-catalyzed synthesis Research Themes: His research develops switchable cucurbituril-based systems for light-controlled enzyme activation and artificial signaling networks. Key areas include protein-protein interaction stabilization , thermodynamic modeling , and allosteric nuclear receptor modulation . Publication Trends: Across JACS , Chemical Science , and RSC Chemical Biology , his work from 2017–2023 emphasizes supramolecular tools for biochemical applications. Notable contributions include 100-fold affinity enhancement of 14-3-3 ligands and UV-responsive cucurbituril release mechanisms . Grants: Funded by Netherlands Organization for Scientific Research (NWO) through Gravity program 024.001.035 and VICI grant 016.150.366.
Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.
Professor Malcolm Kadodwala holds the Gardiner Chair within the School of Chemistry at the University of Glasgow. His research spans chiral nanophotonics, surface science, and spectroscopy with applications in biomolecular detection and nanomaterials. He maintains an active laboratory producing high-impact publications in top journals including Nature Nanotechnology, ACS Nano, and JACS. PhD from University of Nottingham Gardiner Chair in School of Chemistry Active research group with extensive international collaborations His research interests focus on three interconnected themes: (1) spectroscopic investigations of electronic properties in nanostructured materials; (2) development of electron-based chirally sensitive spectroscopic techniques; and (3) creation of novel chiroptical spectroscopic probes. Current work emphasizes superchiral fields for ultrasensitive biomolecular detection, chiral plasmonics, and nanoscale light-matter interactions. His group has pioneered techniques for detecting protein conformations and viral structures at unprecedented sensitivity levels. Publication trends show consistent high-impact output with 15+ recent articles (2021-2025) in nanophotonics and chiral sensing. His work bridges physics, chemistry, and biology, with strong emphasis on practical biosensing applications. Key journals include Nano Letters, ACS Nano, and Nature Nanotechnology. PhD from University of Nottingham Professor Kadodwala advises multiple PhD students including Calum Jack, Affar Karimullah, and Ryan Tullius. His research has attracted significant funding including an MRC discipline-hopping grant (Ref. G0902256). He maintains active collaborations with institutions worldwide including EPFL, University of Jena, and Heriot-Watt University. His laboratory specializes in chiral plasmonic nanostructures and superchiral field generation, with applications in disposable biosensors and viral detection platforms. Current projects involve nanoscale control of electronic properties using structured light and development of chiral metasurfaces for advanced optical applications.
Roshan Gunasekara serves as an Assistant Professor in the Department of Neurology at Yale School of Medicine, where he leads the Gunasekara Lab and collaborates with the Grutzendler Lab. His academic journey includes a PhD in Organic Chemistry from Iowa State University (2016) and undergraduate studies in Chemistry at the University of Peradeniya (2010). Dr. Gunasekara's research focuses on molecular recognition in aqueous environments, with particular expertise in designing synthetic receptors for carbohydrates, peptides, and lipids. His work bridges organic chemistry, nanotechnology, and neuroscience applications, developing innovative tools for molecular sensing and isolation. Key research areas include water-soluble fluorescent foldamers, cooperatively enhanced receptors, and nanoparticle-based systems for biomolecular recognition. His publication record demonstrates consistent high-impact contributions to the fields of supramolecular chemistry and molecular recognition, with numerous articles in prestigious journals including Journal of the American Chemical Society and Chemical Communications. His research shows a clear progression from fundamental molecular recognition principles to applications in extracellular vesicle isolation and neuroscientific contexts. Yale Center for Clinical Investigation Award (2019) The Alpha Chi Sigma Research Award (2016) Graduate Research Symposium Award (2015) Frank J. Moore and Thoreen Beth Moore Fellowship Award (2015) Dr. Gunasekara maintains active research collaborations with prominent scientists including Frederic Pincet, Sathish Ramakrishnan, and Themis Kyriakides. His work has significant implications for diagnostic tools, drug delivery systems, and fundamental understanding of molecular interactions in biological systems.
Jian Peng is an Assistant Professor in the Department of Computer Science at the University of Illinois at Urbana-Champaign. His research focuses on computational biology, machine learning, and their applications to protein structure prediction, drug design, and molecular modeling. He has contributed to advancements in antibody engineering, protein-ligand docking, and generative models for biological systems. Key research areas include: Machine Learning for Molecular Modeling Protein Structure Prediction Antibody and Peptide Design Genomics and Single-Cell Analysis Structure-Based Drug Discovery His work emphasizes integrating deep learning techniques with biological datasets to address challenges in precision medicine, drug development, and systems biology. Notable achievements include developing the FastFold system to accelerate AlphaFold training and pioneering flow-based methods for antibody design. Awards include the Overton Prize (2020), recognizing contributions to computational biology. His research has been published in top journals and conferences, spanning topics from protein mutation prediction to geodesic-based immune complex modeling.
Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.
Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Associate Professor Nikolas Fokialakis is affiliated with the Department of Pharmacy at the National and Kapodistrian University of Athens, specifically within the Section of Pharmacognosy and Chemistry of Natural Products. His academic journey includes a PhD in Pharmacognosy, postdoctoral research at the USDA, and advanced degrees in Pharmacognosy and Pharmacy. His research focuses on natural products from plants, microorganisms, and marine organisms, with emphasis on anti-aging compounds, cosmeceuticals, and bioactive molecule discovery. Notable awards include the Arthur Neish Award (2010) and the ASP Award (2006). He holds editorial roles in international societies and has contributed to over 150 publications. His work integrates biotechnology for sustainable production of bioactive agents and explores microbial biodiversity for drug leads. Teaching responsibilities include courses in Pharmacognosy, Biotechnology, and Pharmaceutical Analysis. Education Highlights: PhD in Pharmacognosy (University of Athens, 2004) Postdoc at USDA Natural Products Lab Postgraduate Diploma in Pharmacognosy (2000) Pharmacy Degree (University of Athens, 1998) Research Interests: Isolation of bioactive small molecules from terrestrial and marine sources Anti-aging mechanisms targeting proteostasis Cosmeceutical development using microbial metabolites Phytochemical analysis of Mediterranean plants Publications Trends: Recent work emphasizes marine microbiota for anti-aging agents, pyrrolizidine alkaloid profiling, and sustainable bioengineering of microbes for industrial metabolites. Over 150 indexed articles demonstrate cross-disciplinary impact in natural products research. Awards: 2011-2019: Board Member, Society for Medicinal Plant Research ANR Research Committee (2015-2018) OECD Scholarship (2005-2006) Advising & Grants: Active in mentoring graduate students in natural products and biotechnology projects. Leads EU-funded initiatives on microbial diversity exploitation. Collaborates internationally on marine invertebrate chemistry and cosmeceutical development. Labs/Teams: Coordinates the Pharmacognosy and Natural Products Chemistry lab at University of Athens, focusing on metabolomics and bioactive compound discovery pipelines.
